Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending September 8, 2006. The report serves as a notification of transactions involving Directors, Persons Discharging Managerial Responsibility, or Connected Persons regarding Ordinary Shares of the Company.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is a regulatory disclosure of specific share transactions rather than a financial performance report.
Material Changes
The filing details specific transactions executed on September 7, 2006, involving the GlaxoSmithKline (US) Trust ("the GSK US Trust"):
- The GSK US Trust sold 11 Ordinary Share ADRs on behalf of participants in the GlaxoSmithKline Share Value Plan at a price of $55.68 per ADR.
- The GSK US Trust transferred 25 Ordinary Share ADRs to participants in the GlaxoSmithKline Share Value Plan.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, or discussion of risks and contingencies. It notes that three directors (Dr J-P Garnier, Dr M M Slaoui, and Mr J S Heslop) are interested in shares held in the GSK Trust in the same capacity as other employees or former employees. The notification was made in accordance with Disclosure Rule 3.1.4R(1)(b).
Investor Verification Points
- Verify the total volume of ADRs sold versus transferred under the Share Value Plan.
- Confirm the transaction price of $55.68 per ADR against market prices on September 7, 2006.
- Review the full composition of the GSK US Trust to understand the scope of director interests.